115
Participants
Start Date
December 20, 2021
Primary Completion Date
March 31, 2028
Study Completion Date
March 31, 2028
No intervention.
All subjects that previously received RGX-314 in a parent study
Retinovitreous Associates, LTD, Philadelphia
Johns Hopkins University, Baltimore
Southeast Retina Center PC, Augusta
Tennessee Retina, PC, Nashville
Charles Retina Institute, P.C, Germantown
Vitreoretinal Surgery PLLC, Edina
Retina Consultants of Texas, The Woodlands
Retinal Research Institute, LLC, Phoenix
Vision Research Center Eye Associates of New Mexico, Albuquerque
Sierra eye Associates, Reno
Retina-Vitreous Associates Medical Group, Beverly Hills
Retina Consultants San Diego, Poway
California Retina Consultants, Santa Barbara
California Retina Consultants, Bakersfield
Northern California Retina Vitreous Associates Medical Group Inc, Mountain View
Ophthalmic Consultants of Boston, Boston
Lead Sponsor
AbbVie
INDUSTRY